000			01254nam a2200121Ia 4500
008			220620s9999||||xx |||||||||||||| ||und||
100			_aDu, Lanying||Li, Fang
245		0	_aMERS-CoV
546			_aEnglish[eng]
650			_acell–cell fusion||hDPP4||n/a||therapeutics||animal models||HCoV-229E||Drivers||camels||rabbits||SARS-CoV||MERS-CoV||MVA vaccine||transmission||RBD||MERS-CoV nucleocapsid protein||complement||animal model||pseudotyped virus||combination||MERS-coronavirus||peptide||mouse model||spike protein||receptor-binding domain||prevention and treatment||coronaviruses||coronavirus spike glycoprotein||therapeutic antibodies||vaccine platforms||mutation||severe acute respiratory syndrome coronavirus||pathogenesis||fusion inhibitor||Coronavirus||murine CD8+ T cell epitope||lipidomics||authentic virus||correlates of immunity||vaccines||neutralizing monoclonal antibodies||Middle East respiratory syndrome coronavirus||small-molecule inhibitor||Middle East Respiratory Syndrome Virus||DPP4||pyroptosis||cross-neutralization||inflammation||Qatar||spike proteins||One Health||HKU4||nanobodies||mechanism of action||neutralizing antibody||host factors||UHPLC–MS
856			_uhttps://mdpi.com/books/pdfview/book/1893
942			_cEB
999			_c24890 _d24890